The study isolates, susceptibilities, typing results and clinical aspects.

ainterval (day) of the two isolates.
bDefined by population analysis profile (PAP)–area under the curve (AUC) method (PAP-AUC) (see Materials and Methods).
cNA, did not carry SCCmec.
dThe duration of Vn exposure represents the total length of time that the patient received vancomycin.The VSSA isolate of each pair obtained prior to beginning vancomycin / teicoplanin therapy.
eVAN, vancomycin; TEC, teicoplanin; OXA, oxacillin; LEV, levofloxacin; MFX, moxifloxacin; CIP, ciprofloxacin; IPM, imipenem; MEM, meropenem; AMK, amikacin; FEP, cefepime; CRO, ceftriaxone; CAZ, ceftazidime; CXM, cefuroxime; SCF, cefoperazone-sulbactam; TZP, piperacillin-tazobactam; RIF, rifampin; SXT, sulfamethoxazole-trimethoprim; LZD, linezolid.

a. 两分离株的间隔天数（day）。
b. 通过群体分析轮廓（population analysis profile, PAP）-曲线下面积（area under the curve, AUC）法（即PAP-AUC法）进行定义（详见材料与方法）。
c. NA：未携带SCCmec。
d. 万古霉素暴露时长指患者接受万古霉素治疗的总时长。每一对分离株中的万古霉素敏感金黄色葡萄球菌（VSSA）分离株均采集于万古霉素/替考拉宁治疗开始前。
e. 缩写对应如下：VAN：万古霉素（vancomycin）；TEC：替考拉宁（teicoplanin）；OXA：苯唑西林（oxacillin）；LEV：左氧氟沙星（levofloxacin）；MFX：莫西沙星（moxifloxacin）；CIP：环丙沙星（ciprofloxacin）；IPM：亚胺培南（imipenem）；MEM：美罗培南（meropenem）；AMK：阿米卡星（amikacin）；FEP：头孢吡肟（cefepime）；CRO：头孢曲松（ceftriaxone）；CAZ：头孢他啶（ceftazidime）；CXM：头孢呋辛（cefuroxime）；SCF：头孢哌酮-舒巴坦（cefoperazone-sulbactam）；TZP：哌拉西林-他唑巴坦（piperacillin-tazobactam）；RIF：利福平（rifampin）；SXT：磺胺甲恶唑-甲氧苄啶（sulfamethoxazole-trimethoprim）；LZD：利奈唑胺（linezolid）。